Merck & Co. Inc. (MRK)
Health Care22 articles
Price chart
Why is MRK moving today?
+1.2%MRK is +1.2% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of just now
Merck & Co. Inc. (MRK) overview
Merck is a global pharmaceutical company best known for its oncology, vaccine, and animal-health franchises.
MRK is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Merck & Co. Inc. trades on the NYSE under the ticker symbol MRK. The most recent market data puts the share price at about $146.98. That is up 1.23% on the session. At that price the company is worth roughly $362.62B.
Over the past 52 weeks, MRK has traded between $82.01 and $156.92. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 116.7. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns. MRK also pays a dividend. It yields around 2.34% at the current price.
Key statistics
Source: Yahoo Finance - quote as of just now
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch MRK
MRK is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each MRK story as it breaks, and tags it bullish, bearish or neutral.
Size matters here as well. The S&P 500 is weighted by market value. MRK is large enough that its own share price nudges the whole index. So it is worth watching even for investors who only hold index funds.
What moves MRK
- Earnings. MRK reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from MRK.
- Sector news. Health Care stocks often move together, so a rival's news can move MRK too.
- Index weight. MRK is big enough to move the S&P 500 on its own.
Market Mood
Latest MRK news
Guggenheim Reiterates Merck (MRK) Stock Rating Before Q3 Earnings
Guggenheim has reaffirmed its stock rating for Merck (MRK) as the company prepares to announce its third-quarter earnings. This reiteration comes as investors anticipate the upcoming results to evaluate Merck's financial health and future growth prospects. Merck's performance in the previous quarter will be closely watched to assess any potential impacts on its stock price. The firm's affirmation of the current stock rating suggests confidence in Merck's business strategies and market position. Analysts and investors are likely paying close attention to any guidance provided during the earnings release that may affect future projections for the company. This matter is important for ordinary investors because guidance and earnings reports often influence stock price movements, impacting investment decisions.
Read More: Guggenheim Reiterates Merck (MRK) Stock Rating Before Q3 Earnings
Moderna (MRNA) Rises 9% After Phase 3 Melanoma Study Symposium Slot
Moderna (MRNA) shares surged 9% to $168 after its Phase 3 melanoma vaccine study was selected for the Presidential Symposium slot at the European Society for Medical Oncology congress on October 24. Meanwhile, Merck (MRK) gained 1% and BioNTech (BNTX) increased 2%. The selection highlights the significance of the study, although no new efficacy data was released. This offers a signal to investors that the research may lead to practice-changing developments in cancer treatment, impacting Moderna's evaluation and future opportunities.
Read More: Moderna (MRNA) Rises 9% After Phase 3 Melanoma Study Symposium Slot
Moderna (MRNA) and Merck (MRK) Announce Cancer Vaccine Breakthrough
Moderna (MRNA) and Merck (MRK) have reported a breakthrough in developing a cancer vaccine aimed at preventing melanoma recurrence. This is a significant event, marking progress after a century of unsuccessful attempts in cancer vaccine research. The announcement highlights the collaboration between the two companies, potentially impacting their stock performance and investor interest. Investors may want to monitor the developments closely, as advancements in cancer treatment can influence market dynamics and investment strategies in the healthcare sector.
Read More: Moderna (MRNA) and Merck (MRK) Announce Cancer Vaccine Breakthrough
Moderna (MRNA) Shares Drop 7% After 392% Year-to-Date Surge
Moderna (MRNA) shares fell 7% to $135.22 after a 392% year-to-date increase, as traders took profits. Despite the decline, the stock has seen significant gains, reaching a record high of $176.66 last week. There were no new negative catalysts reported, and profit-taking appears orderly, with high trading volume noted. The company’s recent phase 3 melanoma trial remains a strong point for investors, as the mRNA therapy's positive data continues to support the bullish sentiment. This decline presents an opportunity for investors to reassess positions in Moderna amidst ongoing developments in its key cancer therapies.
Read More: Moderna (MRNA) Shares Drop 7% After 392% Year-to-Date Surge
Moderna (MRNA) Cancer Vaccine Shows 150% Stock Surge Potential
Merck and Moderna announced promising results from a late-stage trial of their cancer vaccine aimed at preventing melanoma recurrence. The trial demonstrated significant efficacy, contributing to a 150% surge in Moderna's stock price. This notable rise translates into a $5 billion loss for short sellers betting against the stock. The trial results mark a pivotal moment in cancer treatment, impacting market perceptions of both companies' potential in oncology therapeutics. This matters for investors as advancements in medical treatments can significantly influence stock valuations and future revenue streams for companies like Moderna (MRNA).
Read More: Moderna (MRNA) Cancer Vaccine Shows 150% Stock Surge Potential
Moderna (MRNA) Shares Double on Melanoma Vaccine Trial Success
Moderna (MRNA) experienced a doubling in share price following positive outcomes from its late-stage melanoma vaccine trial developed in collaboration with Merck. This development is significant as it indicates potential advancements in cancer treatment and may attract investor interest. The success can impact market perceptions of biotechnology stocks, especially those involved in cancer therapies. Strong results in clinical trials can lead to increased funding and partnership opportunities for Moderna, influencing its future growth potential.
Read More: Moderna (MRNA) Shares Double on Melanoma Vaccine Trial Success
Moderna (MRNA) cancer vaccine trial shows positive early results
In its first late-stage trial, a personalized cancer vaccine from Moderna (MRNA) and Merck showed positive results. The trial involved over 1,100 patients with higher-risk melanoma and met key goals, significantly extending time until cancer recurrence compared to Keytruda alone. Following the announcement, Merck's stock rose over 8% and Moderna's shares soared about 100%. The trial's success suggests that this combination could be a significant new treatment option for melanoma, impacting future drug development and potential market dynamics for these companies.
Read More: Moderna (MRNA) cancer vaccine trial shows positive early results
Merck EVP DeLuca sells $5.9M in stock transaction
Merck's (MRK) Executive Vice President, DeLuca, has sold $5.9 million worth of stock. This sale comes as part of a routine exercise of stock options. The transaction is significant as insider selling can sometimes indicate a lack of confidence in the company’s future performance. For investors, such sales can suggest potential caution regarding the stock's short-term outlook, making it important to monitor insider activity.
Read More: Merck EVP DeLuca sells $5.9M in stock transaction
Merck (MRK) Q2 2026 Results Show Revenue Growth Despite Profit Cut
Merck & Co., Inc. (MRK) reported its second-quarter 2026 financial results, noting increased revenue driven by new drug sales. The company raised its revenue outlook, but also reduced its profit guidance due to charges related to deals. Keytruda significantly contributed to the positive performance, leading to better-than-expected results. This revenue growth combined with the outlook adjustments is important for investors, as it indicates how Merck is navigating financial challenges while capitalizing on new products.
Read More: Merck (MRK) Q2 2026 Results Show Revenue Growth Despite Profit Cut
Stocks Pre-Market Moves: McDonald's, Caterpillar, Palantir Insights
Several companies are making notable pre-market moves including McDonald's, Caterpillar, Palantir, and Merck. Each stock's movements can be indicative of market trends and investor sentiment, potentially impacting trading volumes significantly. Investors should monitor these changes as they may affect overall market direction and individual stock performance. This information is crucial for ordinary investors looking to make informed decisions based on market movements.
Read More: Stocks Pre-Market Moves: McDonald's, Caterpillar, Palantir Insights
Merck (MRK) Earnings Outlook: New Launches and Margin Squeeze
Merck (MRK) is preparing for its upcoming earnings report, with expectations on whether new product launches can compensate for declining margins. Analysts are keenly observing how these launches will impact overall profitability. The company faces challenges from a margin squeeze, which requires substantial performance from its new offerings to maintain competitiveness. This earnings report will inform investors whether Merck's strategy is viable moving forward, making it relevant for those interested in the pharmaceutical sector.
Read More: Merck (MRK) Earnings Outlook: New Launches and Margin Squeeze
Merck's (MRK) Cholesterol Pill Lipfendra Gains FDA Approval
Merck (MRK) announced that the U.S. FDA approved Lipfendra, the first oral PCSK9 inhibitor for treating hypercholesterolemia. This approval comes as Merck's Keytruda faces patent expirations in 2028, which could lead to competition from biosimilars. Lipfendra's approval was based on late-stage trials demonstrating significant reductions in LDL cholesterol levels. Analysts suggest Lipfendra could have peak sales potential worth tens of billions of dollars. This matters for investors as Lipfendra diversifies Merck's offerings beyond oncology, potentially stabilizing revenue streams.
Read More: Merck's (MRK) Cholesterol Pill Lipfendra Gains FDA Approval
Merck (MRK) Stock Price Target Raised to $145 by Guggenheim
Guggenheim has increased its price target for Merck (MRK) to $145, citing a favorable outlook for the company's pipeline. This reassessment reflects confidence in Merck's future product offerings, potentially influencing investor sentiment. The updated price target may impact trading volumes and market activity for Merck shares. For ordinary investors, this adjustment suggests a bullish outlook on Merck's stock performance moving forward.
Read More: Merck (MRK) Stock Price Target Raised to $145 by Guggenheim
BMY vs JNJ: Healthcare Revenue Comparison for 2025
In fiscal 2025, Bristol Myers Squibb (BMY) reported revenue of nearly $48.2 billion, a decrease of approximately 0.2% from the previous year, with a net income of roughly $7.1 billion and a net margin of 14.6%. In contrast, Johnson & Johnson (JNJ) achieved approximately $94.2 billion in revenue, reflecting an increase of nearly 6% year-over-year, accompanied by a net income of around $26.8 billion and a net margin of 28.5%. BMY's balance sheet showed a debt-to-equity ratio of 2.6 and a current ratio of 1.3, while its free cash flow reached nearly $12.8 billion. These figures underscore the differing financial health and revenue growth trajectories of these two healthcare companies.
Read More: BMY vs JNJ: Healthcare Revenue Comparison for 2025
Merck's (MRK) pembrolizumab Receives Orphan Drug Status from FDA
Merck's (MRK) pembrolizumab has been granted orphan drug status by the FDA for treatment in neuroendocrine prostate cancer (NEPC). This designation is significant as it provides benefits such as market exclusivity and potential financial incentives for research and development. The orphan drug status can enhance Merck's positioning in the oncology market, potentially leading to increased sales once approved. The market impact could be positive as investors may view this as a step towards expanding Merck's product offerings in a niche area of cancer treatment.
Read More: Merck's (MRK) pembrolizumab Receives Orphan Drug Status from FDA
Merck (MRK), IMAX, Estee Lauder Stocks Showing Premarket Movements
In premarket trading, notable stocks include Merck (MRK), IMAX, and Estee Lauder. Specific price movements and percentage changes were not detailed in this report. Such fluctuations can indicate market sentiment and investor reactions to events or reports influencing these companies. Market participants should monitor these stocks closely as premarket movements can impact openings and trading volumes when the market opens.
Read More: Merck (MRK), IMAX, Estee Lauder Stocks Showing Premarket Movements
Regeneron (REGN) Stock Drops After Melanoma Drug Trial Failure
Regeneron Pharmaceuticals (REGN) recently reported that its key melanoma drug trial did not achieve the desired outcomes compared to Merck’s Keytruda. This failure is significant as it raises concerns about the effectiveness of Regeneron's treatments in a competitive oncology market. Following the announcement, Regeneron's stock price declined, impacting investor sentiment negatively. The precise percentage drop in stock value was not disclosed, but market reactions generally reflect uncertainty surrounding the company's future drug development prospects.
Read More: Regeneron (REGN) Stock Drops After Melanoma Drug Trial Failure
Barclays Lowers Stock Rating for Terns Pharmaceuticals Amid Merck Deal
Barclays has downgraded the stock rating for Terns Pharmaceuticals, citing the recent deal with Merck. This change could influence investor sentiment and trading volumes for Terns Pharmaceuticals as the market reacts to the adjustment in outlook. The specifics of the rating change were not disclosed in the report. Analyst ratings can significantly impact stock prices and market positioning.
Read More: Barclays Lowers Stock Rating for Terns Pharmaceuticals Amid Merck Deal
Halozyme Therapeutics Projects $1.7–$1.8 Billion Revenue Growth in 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the appointment of David Ramsay as interim CFO on March 12, 2026. The company forecasts revenues between $1.7 billion and $1.8 billion for the year, marking a projected increase of 22% to 30%. Notably, CEO Helen Torley projected royalties from the ENHANZE drug-delivery system to reach $1.1–$1.2 billion. Halozyme also has seven ENHANZE products in development and aims for 40 drugs to be approved or in development by 2028, highlighting its growth trajectory despite the ongoing patent litigation with Merck.
Read More: Halozyme Therapeutics Projects $1.7–$1.8 Billion Revenue Growth in 2026
Merck's Winrevair Meets Primary Endpoint in Heart Failure Trial Results
Merck announced that its heart failure treatment, Winrevair, successfully met its primary endpoint in a clinical trial. This achievement is significant as it validates the efficacy of Winrevair in treating heart failure. The trial results are expected to have implications for future market positioning and potential sales growth of the drug. No specific sales figures or market impact percentages were disclosed in the announcement.
Read More: Merck's Winrevair Meets Primary Endpoint in Heart Failure Trial Results
Merck Announces $6.7 Billion Acquisition of Terns Pharmaceuticals
Merck has announced a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion. This acquisition is seen as part of Merck's strategy to expand its oncology portfolio and strengthen its pipeline. The deal aligns with Merck's focus on innovative drug development. The transaction is expected to close in the fourth quarter of 2023, pending regulatory approvals.
Read More: Merck Announces $6.7 Billion Acquisition of Terns Pharmaceuticals
Merck Pursues $6 Billion Acquisition of Terns Pharma, Reports FT
Merck & Co. is reportedly finalizing a deal to acquire Terns Pharma for approximately $6 billion. This acquisition may influence market dynamics in the biotech sector, as Merck aims to expand its product portfolio. The completion of this deal could affect Merck's stock performance and investor sentiment towards its future growth trajectory. No specific trading volumes or stock price changes were provided in relation to this news.
Read More: Merck Pursues $6 Billion Acquisition of Terns Pharma, Reports FTMore Health Care stocks
Frequently asked questions
Is Merck & Co. Inc. in the S&P 500?
Yes. Merck & Co. Inc. trades as MRK and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is MRK in?
MRK sits in the Health Care sector of the S&P 500.
Where can I find the latest MRK news?
Right here. This page collects recent MRK news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Merck & Co. Inc.'s stock price?
MRK last traded at about $146.98. Prices move all through the session, so this is the latest quote rather than a live one.
What is Merck & Co. Inc.'s market cap?
MRK is worth roughly $362.62B. Market cap is the share price times the number of shares outstanding.
What is MRK's P/E ratio?
MRK trades at a trailing P/E ratio of about 116.7. The ratio compares the share price with earnings per share over the past year.